Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Up 53.3% in December

Repare Therapeutics Inc. (NASDAQ:RPTX) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,300,000 shares, a growth of 53.3% from the December 15th total of 847,800 shares. Based on an average trading volume of 380,100 shares, the days-to-cover ratio is currently 3.4 days. Currently, 4.3% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Repare Therapeutics in a report on Friday, November 8th. Bloom Burton lowered Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 10th. Lifesci Capital reissued a “market perform” rating on shares of Repare Therapeutics in a research report on Friday, December 13th. Finally, Stifel Nicolaus reduced their target price on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 13th.

Repare Therapeutics Price Performance

NASDAQ:RPTX remained flat at $1.28 during midday trading on Friday. 189,272 shares of the company traded hands, compared to its average volume of 500,187. Repare Therapeutics has a 12-month low of $1.20 and a 12-month high of $8.49. The firm has a market capitalization of $54.41 million, a P/E ratio of -0.64 and a beta of 0.88. The stock has a fifty day moving average of $2.28 and a two-hundred day moving average of $2.97.

Institutional Trading of Repare Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in RPTX. Barclays PLC lifted its stake in Repare Therapeutics by 1,471.7% in the third quarter. Barclays PLC now owns 8,330 shares of the company’s stock valued at $29,000 after buying an additional 7,800 shares during the last quarter. Vontobel Holding Ltd. increased its holdings in shares of Repare Therapeutics by 20.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock valued at $83,000 after acquiring an additional 4,000 shares during the period. XTX Topco Ltd acquired a new stake in Repare Therapeutics during the 2nd quarter worth $110,000. Exchange Traded Concepts LLC boosted its stake in Repare Therapeutics by 21.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock worth $174,000 after purchasing an additional 8,809 shares during the period. Finally, Stifel Financial Corp increased its stake in Repare Therapeutics by 36.4% in the third quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock valued at $178,000 after purchasing an additional 13,800 shares during the period. 85.09% of the stock is owned by hedge funds and other institutional investors.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.